Whitehawk Therapeutics Presents Analyses Supporting PTK7 as Target in Lung Cancer

Whitehawk Therapeutics presented real-world analyses at the WCLC 2026 conference, supporting PTK7 as a durable target for antibody-drug conjugates (ADCs) in EGFR wild-type non-small cell lung cancer (NSCLC).

The company's analysis indicated that PTK7 expression remained stable following standard-of-care therapies. This finding suggests PTK7's relevance as a target in second- or later-line treatment for patients with EGFR wild-type NSCLC.

These results reinforce the scientific rationale for Whitehawk's next-generation PTK7-directed ADC, HWK-007, which is currently in Phase 1 development. The drug is designed to target the PTK7 molecule on cancer cells.

The analysis was based on real-world data from patients receiving standard treatments. The presentation at WCLC 2026 offers insights into PTK7's potential role in therapeutic strategies.